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Inhibition of Lipolysis Reduces [~l-Adrenoceptor- 
Mediated Thermogenesis in Man 
S.L.H. Schiffelers, E.M.C. Brouwer, W.H.M. Saris, and M.A. van Baak 
The purpose of the study was to investigate whether the increase in energy expenditure and lipid oxidation during 
I~l-adrenergic stimulation is caused by the concomitant increase in iipolysis. Twelve healthy male subjects participated in three 
trials: no-LIP/-, inhibition of lipolysis by pretreatment with acipimox followed by saline infusion; -/BETA, no pretreatment, with 
dobutamine infusion to stimulate I~l-adrenoceptors; and no-LIP/BETA, pretreatment with acipimox followed by dobutamine 
infusion. Inhibition of lipolysis did not affect baseline energy expenditure, but decreased lipid oxidation and increased 
carbohydrate oxidation. Energy expenditure and lipid oxidation increased significantly during 13~-adrenergic stimulation, but 
this increase was significantly smaller when iipolysis was inhibited ([baseline v infusion period] energy expenditure: -/BETA, 
5.15 -+ 0.16 v6.11 -+ 0.26 kJ/min, P< .001; no-LIP/BETA, 5.28 ± 0.17 v5.71 ± 0.19 kJ/min, P< .01; lipid oxidation: -/BETA, 
0.059 ± 0.004 v 0.073 _+ 0.006 g/min, P < .01; no-LIP/BETA, 0.034 -+ 0.005 v 0.039 +_ 0.006 g/min, P < .05). Baseline plasma 
glycerol and nonesterified fatty acid (NEFA) concentrations decreased after inhibition of lipolysis. Glycerol and NEFA increased 
significantly during I~-adrenergic stimulation alone (glycerol, 65.0 ± 5.3 v 117.0 -4- 10.9 Fmol/L; NEFA, 362 ___ 24 v 954 -+ 89 
ixmol/L; both P < .001). Concomitant administration of acipimox prevented a substantial part of the increase in lipolysis 
during ~l-adrenergic stimulation, but the increase in plasma glycerol and NEFA remained significant (glycerol, 40.4 ± 2.2 v 
44.8 --. 2.2 i~mol/L; NEFA, 118 _+ 18 v160 ± 19 i~mol/L; both P < .05). In conclusion, a reduced availability of plasma NEFA was 
associated with a reduced increase in energy expenditure and lipid oxidation during I~l-adrenergic stimulation in man. 
Copyright© 1998by W.B. Saunders Company 
T HE SYMPATHETIC NERVOUS system plays a role in energy metabolism. Previous studies in humans have 
shown that mainly [31- and [32-adrenoceptors are involved in 
sympathetically mediated thermogenesis, whereas cq- and 
c~2-adrenoceptors do not have an important role. 1,2 The role of 
the [33-adrenoceptor in human thermogenesis is still debated? ,4 
and this will be the case until a specific agonist or antagonist for 
the human [33-adrenoceptor is available. 
It is still uncertain which processes are responsible for the 
sympathetically mediated thermogenesis and in which tissues 
these processes are localized. [31-adrenoceptors are found in 
adipose tissue, heart, and brain, while [32-adrenoceptors are 
present in skeletal muscle, blood vessels, and liver. Infusion of 
the endogenous catecholamines pinephrine and norepineph- 
rine leads to an increase in adipose tissue lipolysis 5,6 and 
whole-body 7,8 and skeletal muscle 5lipid oxidation. Infusion of 
the nonselective [3-agonist isoprenaline also leads to an increase 
in lipolysis and lipid oxidation. 9 
Recent studies showed an increase in lipolysis, lipid oxida- 
tion, and energy expenditure during [31-adrenergic stimula- 
tion with dobutamine, l° H The increase in lipolysis can be 
explained by the presence of [3~-adrenoceptors in adipose tissue. 
The increase in lipid oxidation and thermogenesis is assumed 
to be localized predominantly in skeletal muscle, 5,9 but this 
tissue contains mainly [32-adrenoceptors and presumably no 
[31-adrenoceptors. 12 [31-Adrenergic stimulation therefore is not 
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likely to increase energy expenditure and lipid oxidation by 
direct stimulation of skeletal muscle. We therefore hypothesize 
that the elevated levels of nonesterified fatty acid (NEFA) in 
blood (caused by increased lipolysis due to [31-adrenoceptor 
stimulation) induce the increase in energy expenditure and lipid 
oxidation during 131-adrenergic stimulation. To investigate this 
possibility, we inhibited lipolysis with acipimox (a long-acting 
nicotinic acid derivate) and stimulated the [31-adrenoceptors 
with dobutamine to determine whether a reduced availability of 
plasma NEFA would result in a reduced increase in energy 
expenditure and lipid oxidation. 
SUBJECTS AND METHODS 
Subjects 
Twelve male subjects aged 25.0 + 1.6 years (mean + SEM; range, 
19 to 41) participated inthe study. Their body weight was 73.8 + 3.0 kg 
(range, 57.2 to 93.1), body mass index 22.8 _+ 0.8 kg/m z(range, 18.5 to 
27.8), and fat percentage 12.3% -- 1.6% (range, 5.2% to 22.4%). The 
subjects were healthy and taking no medication at the time of study. The 
study was reviewed and approved by the Ethics Committee of 
Maastricht University, and all subjects provided informed consent 
before participating, 
Experimental Design 
The subjects participated inthree trials performed in random order. In 
trial no-LIP/-, lipolysis was inhibited by pretreatment with acipimox 
(Nedios; Byk Nederland, Zwanenburg, The Netherlands), after which 
saline was given as a placebo infusion. In trial -/BETA, no pretreatment 
was given; only dobutamine (Dobax; Byk Nederland) was infused to 
stimulate [3radrenoceptors. In trial no-LIP/BETA, pretreatment with 
acipimox was followed by infusion with dobutamine. No placebo 
capsule was given for acipimox, since blinding could not be obtained. 
The flushing observed after acipimox would clearly distinguish acipi- 
mox from placebo. The study design was single-blind for dobutamine. 
Subjects were fasted overnight and arrived at the laboratory by car or 
bus to minimize the amount of physical activity before the tests. 
Experiments tarted at 8:00 or 9:30 AM, with each subject always 
starting at the same time. At least 3 days separated consecutive t sts. 
Room temperature was kept at 21 ° to 23°C. 
The capsule of acipimox (250 rag) was administered 90 minutes 
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before the start of the experiment (Fig 1). On arrival at the laboratory, a 
cannula was inserted into a forearm vein, after which measurements of 
the energy expenditure, respiratory exchange ratio (PER), heart rate, 
and blood pressure were started with the subject in a semisupine 
position. After a 30-minute baseline period, a continuous infusion of 
dobutamine (5gg/kg body weight, min) or saline was administered for 
30 minutes. At the end of each 30-minute period, a venous blood sample 
was taken. The infusion was stopped prematurely if the heart rate 
increased by more than 30 beats per minute (bpm) and/or mean blood 
pressure increased by more than 30 mm Hg. This occurred once during 
the study. 
Clinical Methods 
Body density was determined by hydrostatic weighing with simulta- 
neous lung volume measurement (Volugraph 2000; Mijnhardt, The 
Netherlands). Body composition was calculated according to the Siri 
formula. 13 The whole-body energy expenditure and RER were mea- 
sured by a home-made open-circuit ventilated-hood system. The 
volume of air drawn through the hood was measured by a dry-gas meter 
(Schlumberger, Dordrecht, The Netherlands), and the composition of 
inftowing and outflowing air was analyzed by a paramagnetic 02 
analyzer (Servomex, Crowborough, UK) and an infrared CO2 analyzer 
(Hartmann and Braun, Frankfurt, Germany). The airflow rate and 02 
and CO2 concentration fthe inflowing and outflowing air were used to 
compute 02 consumption and CO2 production on-line through an 
automatic acquisition system connected to a personal computer. The 
energy expenditure and RER were calculated according to the formula 
proposed by Weir. 14 Energy expenditure and RER values were averaged 
over the last 10 minutes of each 30-minute period uring which a steady 
state occurred. Carbohydrate and lipid oxidation rates were calculated 
from 02 consumption and CO2 production rates as described by 
Ferrannini, is assuming that protein oxidation accounted for 15% of 
energy expenditure, and were averaged over the last 10 minutes of each 
30-minute period. The heart rate was monitored continuously by 
conventional electrocardiography and recorded at the end of each 
5-minute interval. Heart rate values were averaged over the last 10 
minutes of each 30-minute period and used for further analysis. Blood 
pressure was measured by an automated blood pressure device (Tono- 
print; Speidel & Keller, Jungingen, Germany) after 20 minutes in each 
30-minute interval. The mean values of four measurements per interval 
were computed and used for further analysis. 
Analytical Methods 
Blood samples were preserved in sodium-EDTA (20 ~L 7.5%-wt/vol 
Na-EDTA per 1 mL blood) and immediately centrifuged for 10 minutes 
at 3,000 rpm at 4°C. The plasma was transferred to microtest tubes, 
Indirect calorimetry 
Dobutamine / saline 
• • Blood pressure 
I~ Blood sampling 
• Acipimox / nothing / /  
-90 0 30 60 Time (min) 
Fig 1. Experimental study design. Twelve male subjects partici- 
pated in 3 randomized trials: no-UP/-, inhibition of lipolysis by 
pretreatment with acipimox followed by saline infusion; -/BETA, no 
pretreatment, with dobutamine infusion to stimulate ~l-adrenocep- 
tors; no-LIP/BETA, pretreatment with acipimox followed by dobuta- 
mine infusion. 
rapidly frozen in liquid nitrogen, and stored at -60°C until further 
analysis. The plasma NEFA concentration was measured with a NEFA 
C kit (99475409; Wako, Neuss, Germany), and the plasma glycerol 
concentration was measured with a glycerol kit (148270; Boehringer, 
Mannheim, Germany), both on a Cobas-Fara centrifugal analyzer 
(Roche Diagnostica, Basel, Switzerland). The plasma glucose concen- 
tration was measured with a glucose kit (Unimate 5, 0736724; Roche), 
and plasma lactate was determined by the method of Gntmann and 
Wahlefeld, 16 both on a Cobas-Bio centrifugal nalyzer. Plasma insulin 
was determined with a double-antibody radioimmunoassay (Insulin 
RIA 100; Pharmacia, Uppsala, Sweden). 
Data Analysis 
The data are presented as the mean _+ SEM. Comparison of data 
between the baseline and infusion periods within a trial was made with a 
Student paired t test. Comparison of data at baseline or during the 
infusion period among trials was performed with a repeated-measures 
ANOVA. Post hoc testing was performed with a Student paired t test, 
and P values for post hoc comparisons were corrected according to 
Bonferroni's inequalities. A P value less than .05 was regarded as 
statistically significant. 
RESULTS 
Energy Expenditure, RER, and Substrate Oxidation 
Inhibition of lipolysis did not affect energy expenditure at 
baseline (Fig 2). Energy expenditure increased from 5.15 + 
0.16 to 6.11 +_ 0.26 kJ/min (P < .001) during [31-adrenergic 
stimulation alone, and from 5.28 _+ 0.17 to 5.71 _+ 0.19 kJ/min 
(P < .01) during [31-adrenergic stimulation with concomitant 
inhibition of lipolysis. The increase in energy expenditure was 
significantly reduced when lipolysis was inhibited (-/BETA v 
no-LIP/BETA, 0.93-+ 0.15 v 0.43 +_ 0.10 kJ/min, P < .05). 
The RER increased significantly at baseline when tipolysis was 
inhibited (Fig 2). The RER decreased during the infusion period 
in all trials, but this decrease was only significant during 
[~l-adrenergic stimulation alone. 
Baseline carbohydrate oxidation was significantly higher and 
baseline lipid oxidation was significantly lower after inhibition 
of lipolysis (Fig 3). Carbohydrate and lipid oxidation did not 
change significantly during saline infusion. Carbohydrate oxida- 
tion also did not change during [31-adrenergic stimulation with 
or without concomitant inhibition of lipolysis. Lipid oxidation 
increased from 0.059 + 0.004 to 0.073 + 0.006 g/rain (P < .01) 
during [31-adrenergic stimulation alone. When lipolysis was 
inhibited, lipid oxidation increased from 0.034 -+ 0.005 to 
0.039 _+ 0.006 g/min during [31-adrenergic stimulation (P < .05). 
The increase in lipid oxidation was significantly reduced when 
lipolysis was inhibited (-/BETAv no-LIP/BETA, 0.015 _+ 0.004 
v 0.006 + 0.002 g/rain, P < .05). 
Blood Parameters 
Baseline plasma concentrations of glycerol and NEFA de- 
creased significantly after inhibition of lipolysis (Fig 4). The 
plasma glycerol concentration did not change during saline 
infusion, but plasma NEFA decreased slightly further from 113 
to 93 ~mol/L (P < .001). Plasma glycerol and NEFA increased 
significantly during [31-adrenergic stimulation alone (glycerol, 
65.0 -+ 5.3 v 117.0 _+ 10.9 ~mol/L; NEFA, 362 + 24 v 954 + 89 
~mol/L; both P < .001). After inhibition of lipolysis, plasma 
glycerol and NEFA still increased slightly but significantly 
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significantly during [31-adrenergic stimulation alone (-/BETA), 
but did not change when lipolysis was inhibited (no-LIP/- 
and no-LIP/BETA). Plasma lactate concentrations were simi- 
lar at baseline. Plasma lactate decreased significantly during 
[31-adrenergic stimulation without the preceding intervention 
(-/BETA). Plasma potassium levels were significantly different 
among trials at baseline and during infusion (Table 1). Post hoc 
testing showed no statistically significant differences between 
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Fig 2. Energy expenditure and RER (mean +- SEM, N = 12) during 
baseline period (11) with or without inhibition of lipolysis (no-LIP) by 
acipimox and during infusion ([~) of saline or dobutamine to stimulate 
I~l-adrenoceptors (BETA). Student paired t test corrected for Bonfer- 
roni inequalities, baseline vinfusion period: *P < .05, ***P  < .001. 
during [3t-adrenergic stimulation (glycerol, 40.4-+ 2.2 v 
44.8 - 2.2 gmol/L; NEFA, 118 +- 17 v 160 _+ 19 ~mol/L; both 
P < .05). The increases in plasma glycerol and NEFA were 
significantly reduced when lipolysis was inhibited (-/BETA v 
no-LIP/BETA: glycerol, 52.0 _+ 10.2 v4.4 - 1.8 gmol/L; NEFA, 
591 _+ 87 v 42 -+ 16 ~rnol/L; both P < .001). Plasma glucose 
decreased at baseline after inhibition of lipolysis (Table 1). 
Plasma glucose decreased significantly during [31-adrenergic 
stimulation. This decrease was not affected by inhibition of 
lipolysis (-/BETA v no-LIP/BETA, 0.33 -+ 0.04 v 0.33 -+ 0.03 
gmol/L). The baseline plasma insulin concentration was not 
affected by inhibition of lipolysis. Plasma insulin increased 
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Fig 3. Lipid and carbohydrate oxidation (mean +- SEM, n = 12) 
during baseline period (11) with or without inhibition of lipolysis 
(no-LIP) by acipimox and during infusion ([~) of saline or dobutamine 
to stimulate 131-adrenoceptors (BETA). Student paired ttest corrected 
for Bonferroni inequalities, baseline v infusion period: *P < .05, 
***P< .01. 
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Fig 4. Plasma NEFA and glycerol concentrations (mean _+ SEM, 
n = 12) during baseline period (ll) with or without inhibition of 
lipolysis (no-LIP) by acipimox and during infusion (v1) of saline or 
dobutamine to stimulate ~l-adrenoceptors (BETA). Student paired t 
test corrected for Bonferroni inequalities, baseline v infusion period: 
*P  < .01, ***P  < .001. 
Heart Rate and Blood Pressure 
The hem't rate did not differ among trials at baseline, nor did it 
change during saline infusion or [3Fadrenergic stimulation 
(baseline v infusion period: no-LIP/-, 58 -+ 3 v 58 + 3 bpm; 
-/BETA, 56 -+ 3 v 57 _+ 2; no-LIP/BETA, 55 -+ 3 v 56 + 2). 
Baseline values for systolic and diastolic blood pressure were 
not different among trials (no-LIP/-, 119/80 _+ 2/2 mm Hg; 
-/BETA, 122/76 _+ 2/2; no-LIP/BETA, 120/80 + 2/2). Saline 
infusion had no effect on systolic and diastolic blood pressure. 
Systolic blood pressure increased (P < .001) and diastolic 
blood pressure decreased (P < .05) to a similar extent during 
[31-adrenergic stimulation alone and ]31-adrenergic stimulation 
with concomitant i hibition of lipolysis (-/BETA, 171/65 _+ 413 
mm Hg; no-LIP/BETA, 167/69 -+ 4/3) (Fig 5). 
Almost every subject showed an increase in energy expendi- 
ture, lipid oxidation, and lipolysis during [31-adrenergic stimula- 
tion with or without concomitant inhibition of lipolysis. Only 
two of 12 subjects howed no change in the lipid oxidation or 
lipolysis rate during the no-LIP/BETA trial. No subject re- 
sponded in an opposite direction. Expression of the above- 
mentioned data per kilogram of fat-free mass did not change the 
interpretation f this study. 
DISCUSSION 
The present study was performed to investigate he mecha- 
nism underlying the increase in energy expenditure during 
[31-adrenergic stimulation. Lipolysis was inhibited by acipimox 
and [31-adrenoceptors were stimulated by infusion of dobuta- 
mine to determine whether a reduced availability of plasma 
NEFA would result in a reduced increase in energy expenditure 
and lipid oxidation. 
Inhibition of lipolysis was accomplished by acipimox admin- 
istration. Acipimox suppresses intracelhilar cyclic adenosine 
monophosphate levels in adipose tissue, which leads to a 
reduced hormone-sensitive l pase activity.17 Inour study, plasma 
glycerol and NEFA concentrations decreased significantly after 
acipimox administration, i dicating that a substantial blockade 
of adipose tissue lipolysis was achieved. After pretreatment 
with acipimox, glycerol and NEFA levels remained low during 
saline infusion (no-LIP/-), indicating that inhibition of lipolysis 
was present for the full 60 minutes of the trial. At baseline, the 
reduced availability of plasma NEFA was associated with a 
decrease in lipid oxidation (no-LIP/- and no-LIP/BETA), while 
energy expenditure was unchanged. 
[31-Adrenergic stimulation with dobutamine significantly 
increased lipolysis; plasma glycerol increased 80% and plasma 
NEFA 163% (-/BETA). This is in accordance with prior studies 
by Green et aln and Bhatt et ala0 Inhibition of lipolysis with 
acipimox, for the most part, prevented the increases in plasma 
glycerol and NEFA during [31-adrenergic stimulation, but 
plasma glycerol still increased 11% and plasma NEFA 36% 
(no-LIP/BETA). This indicates that lipolysis was not com- 
pletely blocked by acipimox. Energy expenditure increased 
19% during [31-adrenergic stimulation alone. This is also in 
accordance with the study by Green et al l l  which found an 
increase of 17%. Inhibition of lipolysis reduced the increase in 
energy expenditure to 8% during [31-adrenergic stimulation. 
Lipid oxidation i creased 24% during [31-adrenergic stimulation 
alone. When lipolysis was inhibited, the increase in lipid 
oxidation during [31-adrenergic stimulation was attenuated, but 
it still increased 15%. 
The interpretation of the findings of our study depends 
largely on the specificity of dobutamine asa 131-adrenoceptor 
agonist. Dobutamine predominantly stimulates [31-adrenocep- 
tors, but also has some [32- and eq-adrenoceptor-stimulating 
properties. 11,18 It could therefore directly stimulate skeletal 
muscle [32-adrenoceptors andthus bias our data. We checked for 
this confounder by determining plasma potassium concentra- 
tions. Potassium levels decrease during [32-adrenergic stimula- 
tion, but in our study, no changes in potassium concentrations 
were found during dobutamine infusion. This indicates that no 
significant [32-adrenergic stimulation occurred. This is in agree- 
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Table 1. Plasma Metabolite Concentrations During Baseline With or Without Inhibition of Lipolysis by Acipimox and During Infusion 
of Saline or Dobutamine to Stimulate I~ Adrenoceptors 
no-LIP/- - /BETA no-LIP/BETA ANOVA 
Metabolite Baseline Infusion Baseline Infusion Baseline Infusion Baseline Infusion 
Glucose (mmol/L) 4.72 _+ 0.10 4.57 _+ 0.12 5.06 -- 0.0911 4.73 -- 0.075 4.88 _+ 0.13 4.56 _+ 0.135 P < .001 NS 
Insulin (mU/L) 5.33 _+ 0.48 4.97 _+ 0.50 5.94 _+ 0.67 7.66 _+ 0.67t§ 5.44 _+ 0.48 5.78 _+ 0.54¶ NS P < .01 
Lactate (pmol/L) 771 _+ 56 748 _+ 51 751 _+ 55 666 _+ 49t 782 _+ 41 772 _+ 40 NS NS 
Potassium 
(mmol/L) 4.16 _+ 0.08 4.26 _+ 0.09 * 4.14 _+ 0.06 4.17 _+ 0.07 4.32 _+ 0.08 4.35 _+ 0.08#** P< .05 P< .05 
NOTE. Values are the mean +_ SEM for 12 subjects. 
Student paired ttest corrected for Bonferroni inequalities: within trials, baseline vinfusion period, *P< .05, tP< .01, SP< .001; between trials, 
- /BETA v no-LIP/-, § P < .05, liP < .01; no-LIP/BETA v -/BETA, ¶P < .05, #P < .01; no-LIP/BETA v no-LIP/-, **  P < .05. 
ment with other studies indicating that [32-adrenoceptor- 
mediated effects of dobutamine are relatively small in relation 
to [31-adrenoceptor-mediated effects and become significant 
only at higher doses (-->6 lag/kg -min). I8 In a study by Green et 
Rill (using the same dose of dobutamine as our study), no 
change in the plasma epinephrine concentration a d a decrease 
in plasma norepinephrine was found during [31-adrenergic 
stimulation with dobutamine, indicating no additional stimula- 
tion from endogenous catecholamines. These findings uggest 
that the dose of dobutamine we used was specific for only 
[31-adrenergic stimulation. 
It is suggested by several investigators 8,19 that the catechol- 
amine-induced increase in whole-body energy expenditure may 
be partly explained by the increase in myocardial energy 
expenditure caused by an increase in cardiac output. Myocardial 
energy expenditure can be estimated by the rate-pressure 
product (heart rate × systolic blood pressure). 2°In our study, 
the estimated increase in myocardial energy expenditure during 
[31-adrenergic stimulation would result in an overall increase 
in energy expenditure of 5%. However, whole-body energy 
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Fig 5. Changes in systolic ( i )  and diastolic ([3) blood pressure 
(mean -+ SEM, n = 12) between baseline (with or without inhibition 
of lipolysis [no-LIP] by acipimox) and infusion period (saline or 
dobutamine to stimulate 131-adrenoceptors [BETA]). Student paired t 
test corrected for Bonferroni inequalities, baseline v infusion period: 
**P  < .01, ***P  < .001. 
expenditure increased 19% during [31-adrenergic stimulation 
alone and 8% during [3Fadrenergic stimulation with concomi- 
tant inhibition of lipolysis. The majority of the increase in 
energy expenditure during dobutamine infusion alone therefore 
appears to result from substrate oxidation in other tissues. 
Insulin is assumed toinhibit lipolysis and lipid oxidation. The 
increase in plasma insulin levels during [31-adrenergic stimula- 
tion alone would therefore tend to reduce the increase in lipoly- 
sis and lipid oxidation. However, when lipolysis was inhibited, 
plasma insulin levels remained low during [31-adrenergic stimu- 
lation and thus could not have caused the reduction i  lipolysis 
and lipid oxidation compared with -/BETA. 
Summarizing these results, the reduced availability of plasma 
NEFA after pretreatment wi h acipimox was accompanied bya 
reduced increase in energy expenditure and lipid oxidation 
during [31-adrenergic stimulation. This suggests that part of the 
dobutamine-induced increase in energy expenditure d pends on 
NEFA availability. This may be the part that is localized in 
tissues without [3Fadrenoceptors, such as skeletal muscle, in 
which energy expenditure cannot be directly increased by 
dobutamine. Whether an increased plasma NEFA concentration 
without [31-adrenergic stimulation can increase nergy expendi- 
ture is still debated. After infusion of a lipid-heparin mixture 
that increases the plasma NEFA concentration, some studies 
found no change in energy expenditure 21 or lipid oxidation, 22 
whereas others 23,24 reported significant increases in energy 
expenditure. Our study is not able to answer the question as to 
whether the increased NEFA availability stimulates lipid oxida- 
tion, which in turn increases energy expenditure, or whether the 
increased NEFA availability stimulates energy expenditure, 
which is met by oxidation of more fat. The recent discovery of 
uncoupling proteins 2 and 3 in human skeletal muscle, which 
probably are upregulated by NEFA, would support he second 
possibility. 25 
In conclusion, 131-adrenergic stimulation with dobutamine 
caused an increase in lipolysis, thermogenesis, and lipid oxida- 
tion. Simultaneous inhibition of lipolysis with acipimox was 
associated with a reduced increase in thermogenesis and lipid 
oxidation during [3Fadrenergic stimulation. 
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